Part the Cloud Translational Research for Alzheimer’s Disease Program: Combination Therapies Program (PTC-CTP)

This program will support combination strategies that bring together at least two drug approaches, with optional inclusion of additional drug and or behavioral intervention components, to accelerate innovative, biomarker-informed combination therapies into clinical testing.

Each Phase 2-3 PTC award is limited to a total of $2M USD (direct and indirect costs) for a duration of two to three years. In very rare instances, up to $3M USD may be considered, on a case-by-case basis.

Phase 1 projects are limited to a total of $1M USD total costs. Indirect costs are only allowed for non-profit organizations, and are capped at 10 percent of total direct costs, inclusive of indirect costs for any subcontracts.